XML 71 R64.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information - Schedule of Segment Information, Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information [Line Items]        
Revenue $ 71,553 $ 58,879 $ 142,427 $ 111,322
Cost of revenue 20,165 17,999 38,873 34,978
Research and development 19,153 24,134 42,776 48,337
Sales and marketing 26,414 23,573 52,760 46,620
General and administrative 21,168 17,786 42,152 35,185
Share-based compensation expense 11,119 13,359 23,047 25,506
Segment non-cash and restructuring items (12,520) (15,141) (26,865) (29,081)
Other unallocated items [1] (30,268) (6,643) (37,716) (13,316)
Net loss (39,941) (25,593) (59,956) (55,423)
Operating Segments        
Segment Reporting Information [Line Items]        
Revenue 71,553 58,879 142,427 111,322
Cost of revenue 18,891 16,535 36,135 32,420
Research and development 18,657 23,551 41,817 47,198
Sales and marketing 24,796 21,954 49,538 43,367
General and administrative 13,489 10,131 26,008 19,633
Depreciation and amortization expense 3,235 4,040 6,621 8,326
Impairment of long-lived assets [2]     347  
Restructuring expense [2] 77   720  
Share-based compensation expense [3] 9,208 11,101 19,177 20,755
Adjusted EBITDA [4] 2,847 (3,809) 4,625 (13,026)
Operating Segments | MRD        
Segment Reporting Information [Line Items]        
Revenue 66,168 49,938 133,261 93,659
Cost of revenue 18,891 16,535 36,135 32,420
Research and development 8,610 8,498 17,836 17,657
Sales and marketing 24,796 21,954 49,538 43,367
General and administrative 13,489 10,131 26,008 19,633
Depreciation and amortization expense 2,409 2,455 4,790 5,118
Restructuring expense [2] 77   325  
Share-based compensation expense [3] 6,248 6,637 12,395 12,101
Adjusted EBITDA [4] 9,116 1,912 21,254 (2,199)
Operating Segments | Immune Medicine        
Segment Reporting Information [Line Items]        
Revenue 5,385 8,941 [1] 9,166 17,663 [1]
Research and development 10,047 15,053 [1] 23,981 29,541 [1]
Depreciation and amortization expense 826 1,585 [1] 1,831 3,208 [1]
Impairment of long-lived assets [2]     347  
Restructuring expense [2]     395  
Share-based compensation expense [3] 2,960 4,464 [1] 6,782 8,654 [1]
Adjusted EBITDA [4] (6,269) (5,721) [1] (16,629) (10,827) [1]
Unallocated Corporate        
Segment Reporting Information [Line Items]        
Other segment items [5] 5,393 5,658 11,169 10,811
Unallocated Corporate | Immune Medicine        
Segment Reporting Information [Line Items]        
Other segment items [5] $ 5,393 $ 5,658 [1] $ 11,169 $ 10,811 [1]
[1] Costs related to Digital Biotechnologies, Inc. are no longer included as Immune Medicine costs and have been reclassified to the “other unallocated items” total.
[2] Represents expenses recognized in conjunction with a restructuring that primarily impacted research and development activities.
[3] Represents share-based compensation expense related to various awards. See Note 12, Equity Incentive Plans for details on our share-based compensation expense.
[4] Segment Adjusted EBITDA is a non-GAAP financial measure we define as revenue less expenses, adjusted for depreciation and amortization expense, impairment costs for long-lived assets, restructuring expense and share-based compensation expense generated and incurred, respectively, by each segment. Adjusted EBITDA related to our unallocated category is included in the calculation of consolidated Adjusted EBITDA but not shown above in the breakout and aggregation of segment Adjusted EBITDA.
[5] For the Immune Medicine segment, includes all Immune Medicine operating expenses, other than research and development expenses.